Discontinuation of lithium because of side effects.

J Psychiatry Neurosci

Department of Psychiatry, Dalhousie University, Halifax, NS.

Published: November 2011


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201996PMC
http://dx.doi.org/10.1503/jpn.110117DOI Listing

Publication Analysis

Top Keywords

discontinuation lithium
4
lithium side
4
side effects
4
discontinuation
1
side
1
effects
1

Similar Publications

Potentially dangerous interactions between psychotropic medications and medicines frequently used in anesthesia pose substantial risks regarding perioperative care. We aimed to review the recommendations of perioperative psychotropic medication management and to discuss potential interactions of the frequently used psychotropic drugs with anesthetic agents. PubMed/MEDLINE and Scopus databases were searched for the review articles reporting data on the perioperative management of psychotropic medications.

View Article and Find Full Text PDF

Lithium is a key treatment for bipolar disorder but is associated with significant endocrine and metabolic side effects, particularly lithium-induced hyperparathyroidism (LIH). Characterized by hypercalcemia and inappropriately normal or elevated parathyroid hormone (PTH) levels, LIH can lead to skeletal complications such as osteoporosis. Managing this condition is particularly challenging in psychiatric patients due to adherence issues with follow-up care.

View Article and Find Full Text PDF

Background: Medication-related breastfeeding discontinuation occurs when women stop breastfeeding due to medication. While many medicines are safe during breastfeeding, women needing medication are less likely to continue. This disconnect may reflect avoidable barriers and missed opportunities for support.

View Article and Find Full Text PDF

Purpose: Individuals with Bipolar II disorder (BD-II) face high rates of depression and have limited FDA-approved treatments, leading to treatment delays and poor functioning. Although not commonly recommended, monoaminergic antidepressants are prescribed to 50% of patients. This review updates the evidence for second-generation antidepressant (SGAD) monotherapy in treating acute BD-II depression.

View Article and Find Full Text PDF

Lithium, commonly used in the treatment of bipolar disorders, is primarily known for causing neurological and renal side effects. However, cardiac side effects are rarely reported. We present a case of chronic lithium toxicity in an 80-year-old woman.

View Article and Find Full Text PDF